Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGAM1 | P18669 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.46 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CCR9 | P51686 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502755 | 0.91 | CCR2 (0.47) | PGAM1HSPD1PTPN2PTPN1PTPN5 | |
| SCHEMBL4500651 | 0.87 | CCR2 (0.46) | PGAM1HSPD1PTPN2PTPN1PTPN5 | |
| SCHEMBL4496936 | 0.86 | SLC22A12 (0.44) | PGAM1HSPD1PTPN2PTPN1PTPN5 | |
| SCHEMBL4489745 | 0.86 | IDH2 (0.50) | HSPD1PTPN2PTPN1PTPN5HSPE1 | |
| SCHEMBL4493785 | 0.83 | EDNRB (0.48) | HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL4493846 | 0.83 | HSD11B1 (0.54) | HSD11B1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL9982685 | 0.78 | AGTR1 (0.47) | HSD11B1LMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL31566757 | 0.77 | ERAP1 (0.55) | PGAM1HSPD1PTPN2PTPN1PTPN5 | |
| SCHEMBL4515079 | 0.74 | AGTR1 (0.46) | HSD11B1LMNAALDH1A1SLC22A12 | |
| SCHEMBL4491234 | 0.74 | PFKFB3 (0.41) | HSD11B1LMNAMAPTHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | claimed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | claimed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | claimed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | claimed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | claimed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | claimed |
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | disclosed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | GPR119, CYP4B1, SLC5A1 | PGAM1 1110/4885HSPD1 3404/4885PTPN2 1008/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | PGAM1 1110/4885HSPD1 3404/4885PTPN2 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.